Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on March 24, 2015, covering events that occurred on March 23, 2015. The filing primarily addresses corporate governance changes and the release of investor materials.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Director Fee: $40,000 annual fee for the new director, prorated for 2015 service.
- Equity Grant: Options to purchase 35,000 shares of common stock.
- Exercise Price: $11.46 per share.
Material Changes
The material change reported is the appointment of Georges Gemayel, Ph.D., to the Board of Directors to fill a vacant seat. Dr. Gemayel was granted stock options subject to a four-year vesting period. No committee assignments were made at the time of appointment.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or specific risk factors. It notes the issuance of a press release and the posting of a new investor presentation on the company website, which are incorporated by reference.
Investor Verification Checklist
- Verify the full text of the March 23, 2015 press release (Exhibit 99.1) for additional context on the appointment.
- Review the new investor presentation posted on the company website for updated strategic or financial information.
- Confirm the vesting schedule details for the 35,000 stock options granted to Dr. Gemayel.
- Check subsequent filings for any committee assignments made to the new director.